Dear Dmitry,

Many thanks for organizing today’s meeting. We have received very useful information and much appreciate your and your colleagues’ efforts.

We are very glad and thankful that Pfizer is committed to proceed with bilateral negotiations with the Ministry.

Within the Covax Platform, Georgia has secured 1.4 mln doses of vaccines for 20% of the country population, however, to guarantee required coverage of the risk groups, based on national vaccine roll-out plan, we kindly request you to consider the possibility of allocation 1 million doses of Pfizer vaccine to Georgia via Direct Supply Agreement. We would much appreciate if you could provide some amount of vaccine in Q2, at the earliest occasion.

The counterpart responsible for vaccine procurement is the Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia.

Hereby we confirm that in line with the Law of Georgia on “Medicines and Pharmaceutical Activities” (Article 11¹³) and corresponding Order N327/n of the Minister of Labour, Health and Social Affairs of Georgia of October 13, 2009 the Ministry will grant the Emergency Use Authorization for the Pfizer vaccine based on WHO Emergency Use Listing and/or Emergency Use Authorization issued by a WHO designated Stringent Regulatory Authorities. The product can be imported with standard labels without additional inserts nor translation in a language other than UN languages be required.

In line with amendment to the “Public Health” Law, the Ministry will be able to complete an agreement with Pfizer immediately to indemnify the manufacturer for product liability claims associated with the use or administration of that vaccine. Article 45⁵ – The temporary liability rule related to the pharmaceutical product against the infection (COVID-19) caused by the novel coronavirus (SARS-CoV-2) https://matsne.gov.ge/en/document/view/21784?publication=33

Covid-19 Vaccine National Deployment Plan, which is approved by the Decree #67 of the Government of Georgia on January 21, 2021, stipulates the intention to manage a number of different vaccines in a national response, including cold chain requirements for any type of vaccine (including -80 0C, -200C and 2-80C regimens).

Once again, we reiterate the importance of our partnership and extend my most sincere gratitude to you and your respective organizations for fruitful collaboration and support.

We remain at your disposal to discuss any further details of our negotiations and looking forward to receiving your feedback.

Thank you again for consideration.

Best regards,



Dear Dmitry

Many thanks for your e-mail. First of all I would like to express our sincere gratitude for providing COVID vaccines via COVAX platform. We hope that the Pfizer/BioNTech BNT162b2 vaccine will successfully be implemented in the country and we will have promising results to share.

Although for the time being we rely on COVAX distribution, we are really keen to explore additional opportunities. In order to further extend our collaboration, I would highly appreciate if you could advice on possibility for bilateral agreement between Pfizer and GoG.

Many thanks for your kind assistance so far. We look forward to receiving the first batch of vaccine late March.

With kindest regards

Tamar

 

პატივისცემით,

თამარ გაბუნია

მინისტრის პირველი მოადგილე

 

Sincerely,

Tamar Gabunia, MD, MPH

First Deputy Minister

 

 

 

 

From: Kozenkov, Dmitry [mailto:Dmitry.Kozenkov@pfizer.com]
Sent: 12 March, 2021 14:46
To: Tamar Gabunia <tgabunia@moh.gov.ge>
Cc: Sultanova, Yuliya <Yuliya.Sultanova@pfizer.com>; Tuyakbayeva, Kamila <Kamila.Tuyakbayeva@pfizer.com>
Subject: regarding COVID-19 vaccine possible donation

 

Dear Madam Gabunia,

 

We have received your request for receiving surplus doses from the State of Israel, which was shared by our colleagues. As the request might be related, but not limited to Pfizer/BioNTech BNT162b2 vaccine candidate, we would like to assure you that both local and global Pfizer teams are acutely aware of the situation in Georgia and we will continue to work with the Government of Georgia to find a way forward. We would also like to underline that Pfizer remains committed to equitable and affordable access for COVID-19 vaccines everywhere around the world, including Georgia.

 

Please be aware that regardless of the route the vaccine is delivered to a country (i.e. a donation, via COVAX facility or a bilateral agreement between a Government and Pfizer), all processes face the same requirements (including, but not limited to storage, transport and product acceptance requirements, etc...), which is why the fastest route continues to be the one we have already been pursuing together in collaboration with the Government of Georgia.

 

We will continue to work closely with You and other relevant bodies of Georgia for bringing the BNT162b2 vaccine to protect the people of Georgia.

 

Best regards,

 

Dmitry Kozenkov Country Manager CauCAR (Caucasus & Central Asia Republics, Mongolia)

Pfizer Export B.V. representative office in Almaty, Kazakhstan